Sabra Health Care REIT (SBRA) Stock

Sabra Health Care REIT gets rated buy, agreeing with consensus, and driven heavily by macro-level demand forecasts for skilled nursing facilities. The stock is undervalued on forward P/FFO vs key peers, and is trading close to its moving average now. The firm has investment-grade ratings from Fitch and Moody's agencies.

Sabra (SBRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sabra Health Care REIT offers a compelling investment opportunity with a reasonable valuation, trading at 13.6x 2024 FFO and 12.9x 2025 FFO. The company benefits from strong industry fundamentals, including an aging population and growing demand for senior living and healthcare facilities. Q3'24 results showed robust performance with occupancy gains and NOI growth, particularly in the SHOP portfolio, indicating effective operational leverage.

Sabra Health Care REIT, Inc. (NASDAQ:SBRA ) Q3 2024 Earnings Conference Call November 1, 2024 1:00 PM ET Company Participants Lukas Hartwich - Senior Vice President, Finance Rick Matros - Chief Executive Officer, President & Chair of the Board Talya Nevo-Hacohen - Chief Investment Officer, Treasurer & Executive Vice President Michael Costa - Chief Financial Officer Conference Call Participants Elmer Chang - Scotiabank John Kilichowski - Wells Fargo Austin Wurschmidt - KeyBanc Juan Sanabria - BMO Capital Michael Griffin - Citi Rich Anderson - Wedbush Alec Feygin - Baird Michael Stroyeck - Green Street Omotayo Okusanya - Deutsche Bank Operator Good day, everyone. My name is Adam, and I will be your conference operator today.

Although the revenue and EPS for Sabra (SBRA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.37 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to FFO of $0.34 per share a year ago.

Sabra Healthcare REIT is showing a strong turnaround with impressive Q2 earnings, driven by increased occupancy and NOI growth, particularly in senior housing. The REIT's deleveraging efforts and strong liquidity position it well for future investments, with no debt maturing before 2026 and investment-grade ratings. Dividend growth is expected to resume in 2025, with management raising AFFO guidance, suggesting potential for share price appreciation despite lagging peers.

Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.36 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to FFO of $0.34 per share a year ago.

High interest rates have pressured businesses, but lower rates are expected to provide relief soon, particularly for REITs. Sabra Health Care REIT is poised to benefit from lower interest rates and an aging population. Despite lower occupancy levels, SBRA is expected to outperform peers with solid growth of 4.75% over the next 3 years.